The data, analyzed from biological samples donated by GlaxoSmithKline, is available on SAEC's website for free, and the group plans to publish the associations later this year. However, an SAEC official said "it would be preliminary to develop a meaningful diagnostic chip off this data."
Despite increasing evidence that the action of some drugs is influenced by patient genetics, testing for such variants has not been widely adopted as part of standard practice, AAAS meeting attendees heard this weekend.
Revenues for the company's diagnostics group increased 3 percent. This division includes molecular diagnostics, which posted a 2 percent dip in revenues, and applied sciences, which recorded an 11 percent increase in sales.